Hybrid Compound, Its Use and Process for Its Preparation

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention pertains to novel hybrid compounds that chemically join aminopyrazole derivatives with peptides (especially D-peptides). These hybrids can specifically target and interfere with harmful protein aggregation, multimerization, or misfolding processes that are implicated in neurodegenerative and protein-aggregation diseases. The compounds are designed to both prevent and disassemble toxic protein structures such as amyloid-beta oligomers, which are associated with Alzheimer's disease, prion diseases, and related disorders. The invention also describes methods for synthesizing these hybrids and their use in pharmaceutical compositions to treat or prevent such conditions.

Use CasesContent extracted from patent full text and abstract with AI.

• Development of new therapeutics for Alzheimer's disease targeting amyloid-beta aggregation.
• Treatment or prevention of prion diseases (e.g., Creutzfeldt-Jakob disease, BSE, Scrapie) by inhibiting prion protein aggregation.
• Treatment of other neurodegenerative diseases driven by aberrant protein aggregation, such as Parkinson's disease.
• Preventive therapies in patients at risk for amyloidosis or diseases with known protein misfolding pathology.
• Development of injectable, oral, or inhalable pharmaceutical formulations to be administered in hospitals or outpatient settings.

BenefitsContent extracted from patent full text and abstract with AI.

• Synergistic effect of hybrid compounds yields higher efficacy at lower concentrations compared to individual components, minimizing side effects.
• Selective targeting of toxic protein aggregates and misfolded proteins, potentially improving safety and reducing off-target toxicity.
• Versatile administration routes (intravenous, subcutaneous, intraperitoneal, topical, aerosol, etc.), broadening clinical applicability.
• Potential to not only prevent but also reverse pathological protein aggregation and synaptic dysfunction.
• Addresses unmet medical needs—only palliative therapies exist for most protein-aggregation diseases, so this approach offers true disease modification.
• Reduces or eliminates harmful amyloid-beta aggregates and can restore neuronal function, as shown in preclinical models.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to a hybrid compound based on aminopyrazol derivatives and peptides, for use as a therapeutic agent in treating illnesses wherein an aberrant protein aggregation or protein multimerization, or a protein folding error, plays a role. The invention further relates to a method for producing said compounds.